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Introduction
A bleeding gastroduodenal ulcer is a potentially life-threatening condition and may represent a major treatment challenge. The H 2 -receptor antagonists were introduced in Norway in the late 1970 for the treatment of peptic ulcer disease and were followed by the proton pump inhibitors (PPIs) in the late 1980s. Eradication regimens for Helicobacter pylori were introduced in south-western Norway in 1992. Effective medical treatment for peptic ulcer disease has therefore now been available in this area for almost 30 years, and a reduction in the incidence of bleeding peptic ulcers might be expected. Studies from the Netherlands 1 and Germany 2 show a stable incidence of ulcer bleeding when comparing the time periods 1993-1994 and 2000, and 1989-1990 and 1999-2000 , respectively. In contrast, a report from Greece shows a 30% decrease in the incidence of peptic ulcer bleeding from 1995 to 2005, 3 and another study from Italy shows a decrease of about 42% from 1983-1985 to 2002-2004 . 4 Use of aspirin, NSAIDs, and the presence of H. pylori infection are recognized as important risk factors for ulcer bleeding. [5] [6] [7] [8] [9] [10] [11] Oral corticosteroid use and current smoking are also reported as independent risk factors. 12 There is a growing elderly population in Norway with an increased intake of low-dose aspirin and NSAIDs. The aim of this study was to analyze time trends in the incidence of peptic ulcer bleeding between 1985 and 2008, and to elucidate the associated risk factors and symptoms prior to admission. The hypothesis was that there would be a time trend of decreased incidence of peptic ulcer bleeding in the population, especially in younger people due to treatment with H 2 -antagonists or PPIs, and/or eradication of H. pylori. In the elderly, more ulcer bleeding was expected due to a suggested increase in the use of aspirin or NSAIDs.
Material and methods inclusion and diagnosis
Patients aged 20 years or older who had been emergency admissions to the surgical or medical department of Haugesund Hospital for acute gastrointestinal (GI) bleeding due to gastric or duodenal ulceration, with signs of serious bleeding such as melena and/or hematemesis, were included in the study. An upper GI endoscopy was performed for diagnosis on the day of admission or the next day in patients with stable circulation. Emergency endoscopy was performed during nights and weekends only in patients with unstable circulation and with signs and symptoms of very serious bleeding. To prevent exclusion of patients with bleeding ulcers from the study due to miscoding, ie, those not recorded as having a bleeding ulcer, the records of all patients with the diagnosis of duodenal or gastric ulcer were reviewed.
Exclusion
Patients with bleeding from malignant ulcers, or Dieulafoy's or Mallory-Weiss lesions were excluded. Endoscopic, surgical and laboratory data were retrospectively collected from the patients' case records and were stored anonymously using a specially designed computer program. Three two-year periods were studied, ie, 1985-1986 versus 2007-2008 and in addition 1995-1996 , when testing and eradication of H. pylori was believed to have been established in this area after its introduction in Norway in 1992.
Diagnostic tests for Helicobacter pylori
Gastric biopsy for the detection of H. pylori was performed at the index endoscopy. If the test was negative or not performed due to massive bleeding, the intention was to repeat the test procedure at a second ambulatory endoscopy, without any treatment with H 2 -antagonists or PPIs in the previous 10 days, to exclude a false-negative test at the index endoscopy. Both a positive urease rapid test within 24 hours and histologic verification were required for diagnosis of H. pylori infection.
hospital catchment population
Every patient with acute GI bleeding in the hospital catchment area was admitted to Haugesund Hospital in 1985-1986 and 2007-2008 . The hospital catchment area did not change during this time. The total population in the catchment area had increased from 96,674 inhabitants in 1985-1986 to 109,240 in [2007] [2008] . The total population and its age distribution for the three study time periods were obtained from the Norwegian official statistics published on the Internet. 13 The total annual incidence rates were calculated by using the mean number of patients with bleeding peptic ulcer versus the mean population in each two-year period. Two age groups, the first being 20-75 years and the second being older than 75 years, were selected to identify any differences according to age. Age-related incidence rates were calculated in parallel with the total incidence rates. Every registered patient was assumed to be under observation for one year in each study period. The rates were expressed per 100,000 person-years of observation. Risk factors and other variables were compared by χ 2 -test or Fisher's exact test when appropriate. The recording of data and the calculations were performed with the Statistica program package (Statsoft Inc., Tulsa, OK).
Results incidence
In total, 306 patients with bleeding duodenal or gastric ulcer were included during the three two-year study periods from January 1, 1985 to December 31, 2008. Incidence rates for all patients and for the two age groups are shown in Table 1 . The total incidence rate of peptic ulcer bleeding in the population did not differ significantly between the three time periods. In the age group 20-75 years, the incidence rate decreased by 54% between 1985-1986 and 2007-2008 (P = 0.001). In those patients older than 75 years, the incidence increased by 49% from the earliest to the last study time period (P = 0.0001). Demographic details of the patients, their previous history of peptic ulcer disease, dyspepsia, and hematemesis prior to admission for a bleeding ulcer are given in Table 2 . The number of patients complaining of dyspepsia prior to ulcer bleeding decreased by 80% between 1985-1986 and 2007-2008 (P = 0.0000 ).
risk factors for bleeding Aspirin and nsAiDs
Use of drugs recognized as causing ulcers or known to contribute to bleeding and the results of H. pylori testing are shown in Table 3 
Tobacco and alcohol
Tobacco and alcohol use did not differ significantly when the three time periods were compared. Numbers of smokers and alcohol intake were small, although the information provided by patients on these issues may have been incorrect. The amount of alcohol intake was not recorded, but all patients included in this group had a period of heavy drinking prior to admission.
Other drugs
No patients were identified to have used clopidogrel as a single antiplatelet drug. A few patients in 2007-2008 may have used clopidogrel in addition to aspirin, but this was not recorded during the study. Concomitant intake of a PPI or H 2 -antagonist was not used by any patient at admission during any of the study time periods.
Helicobacter pylori
The result of H. pylori testing are shown in Penston et al 5 reported a decrease in the incidence of peptic ulcer bleeding of 29% between 1981-1985 and 1986-1990 Table 1 number of patients/population (incidence a ) and age-adjusted incidence of peptic ulcer bleeding in a defined geographical area in norway during the time periods 1985-1986, 1995-1996, and 2007-2008 
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Time trends and risks for peptic ulcer bleeding studied were also significantly older. 14 This is consistent with the results of our study. In contrast, a population-based study by Lanas et al 15 involving 10 hospitals in Spain reported a clear decreasing trend in upper GI admissions between 1996 and 2005. This trend is consistent with other reports from southern Europe. 3, 4 The use of NSAIDs increased in the three studies from southern Europe, 3, 4, 15 as was found in the present study. The different time trends in overall incidence rates between these studies 3, 4, 15 and the present study may reflect a higher prescription rate of H 2 -antagonists, PPIs, or H. pylori eradication regimens in the populations in these countries than in the region of Norway studied here.
Aspirin and nsAiDs
In the present study the increased use of aspirin or NSAIDs between 1985-1986 and 2007-2008 , especially in the older patients, may be a major contributor to the increased incidence of ulcer bleeding in those older than 75 years. Comorbidity and interactions with other drugs which increase the risk for bleeding eg, clopidogrel, may also contribute, reportedly up to 45%. 12 However, the use of aspirin or NSAIDs also increased in the younger age group between 1985-86 and 2007-2008. The decline in the incidence of peptic ulcer bleeding in people younger than 75 years may be the result of a combination of favorable factors, eg, eradication of H. pylori, short-term treatment with H 2 -antagonists or PPIs, or a beneficial change in lifestyle factors in this age group. In 2007-2008, 67% of the bleeding ulcers were attributed to or associated with aspirin or NSAIDs in this study, whereas other studies have reported rates of 46%-80%. 1, 3, 4, 12, 14 Gastric/duodenal ulcer ratio An increased Gu/Du ratio was expected when comparing the earlier and later time periods due to the increased use of aspirin or NSAIDs. This ratio did not change in accordance with the report by Ohmann et al. 2 This may be explained by the low numbers of patients in each study period (Type II error). However, when users of aspirin or NSAIDs versus nonusers were compared, the ratio was about twice as high in each time period. The oral anticoagulant warfarin and low-dose aspirin were also coprescribed in the present study in 2007-2008 which would increase the risk of serious ulcer bleeding. 16 
Dyspepsia
Dyspepsia prior to hospital admission decreased from 60% to 12% between 1985-1986 and 2007-2008 (P = 0.0000). Dyspepsia is a major symptom in chronic peptic ulcer disease, and the increased frequency of patients without dyspeptic complaint prior to an ulcer bleeding is consistent with the findings of Gururatsakul et al and Henriksson et al. 14, 18 This change in symptom suggests an increased ratio of acute versus chronic ulcers caused by increased use of low-dose aspirin or NSAIDs.
Helicobacter pylori
The prevalence of H. pylori infection declined between 1995-1996 and 2007-2008 . The previously reported prevalence of H. pylori infection in 1998-1999 of about 75%-80% [17] [18] [19] is comparable with the prevalence seen in the present study in 1995-1996. The decline in prevalence of H. pylori infection in patients with bleeding ulcers between 1995-1996 and 2007-2008 (P = 0.06), and also in nonusers of aspirin or NSAIDs, may be due to eradication of H. pylori in patients with uncomplicated peptic ulcer disease. The sensitivity of rapid urease testing and histology to detect H. pylori infection have been reported to be 0.67 and 0.70, respectively. 20 The sensitivity of these two tests is assumed to have been similar in 1995-1996 and 2007-2008 
Helicobacter pylori, aspirin, nsAiDs
The combination of H. pylori infection and other risk factors, such as aspirin or NSAIDs, was high in the present study, being 73% and 51% in 1995-1996 and 2007-2008 , respectively. These three risk factors had an impact on the etiology of 90% of bleeding peptic ulcers in the 2007-2008 study period. A study at Beograd 21 identified that about 20% of patients with bleeding ulcers had none of these three risk factors, while Gisbert et al 22 found that only 2% of patients developed bleeding ulcers in the absence of these risk factors. A study from Japan 23 reported a corresponding prevalence of 11%, which is comparable with that in the present study. H. pylori, aspirin, and NSAIDs represent independent and synergistic risk factors both for uncomplicated peptic ulcer disease and for bleeding ulcers. [23] [24] [25] [26] Eradication of H. pylori is recommended before NSAID therapy to reduce the risk for peptic ulcer disease. 27, 28 Eradication is also recommended before the start of low-dose aspirin prophylaxis. [29] [30] [31] The results of the present study support both these recommendations.
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Bakkevold A limitation of this study is its retrospective design which may have introduced bias, eg, from absent data on previous ulcer disease, dyspepsia, oral use of other drugs which may induce or contribute to bleeding, anti-ulcer drugs, and use of tobacco and alcohol. To achieve the most reliable data, especially regarding the use of ulcerogenic drugs and other drugs which may contribute to bleeding, data were recorded from records at hospital admission, from previous hospitalizations, and supplied or corrected with data recorded during the hospital stay and eventually at an ambulatory endoscopy after discharge from hospital. Estimation of ulcer size and classification of bleeding activity may be inaccurate due to the variable time lag between admission and the index endoscopy, as well as observer variation between endoscopists. Significant differences in findings for bleeding activity between the three time periods, ie, clot, black spot, and no signs (Table 4) , need to be validated in future prospective studies. The low number of patients in each time period, especially for interpreting the results according to the two age groups, gives a low power in the statistical analyses and an increased likelihood of Type II error.
Conclusion
The overall incidence of bleeding peptic ulcers between 1985-1986 and 2007-2008 remained unchanged in the population in this area of Norway. However, the incidence decreased by 54% in the age group 20-75 years and increased by 49% in those older than 75 years. The use of aspirin or NSAIDs prior to an ulcer bleeding increased from 31% to 67% between 1985 -1986 , only 10% of the patients with peptic ulcer bleeding were nonusers of low-dose aspirin or NSAIDs and H. pylori negative. Dyspepsia prior to an emergency hospital admission for peptic ulcer bleeding declined from 60% to 12% in the same time period, which suggests an increasing frequency of acute bleeding ulcers caused by the use of ulcerogenic drugs.
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